Only half of medical advice on an online message board dedicated to implanted cardiac defibrillators (ICDs) appears to be accurate, according to preliminary research presented April 7 at the American Heart Association’s Quality of Care and Outcomes Research Scientific Sessions 2018.

The expansion of Medicaid eligibility in Michigan allowed more patients to get coronary revascularization procedures without negatively affecting patient outcomes, suggests a research letter published in the Journal of the American College of Cardiology.

Researchers at the Cleveland Clinic have received a $2.5 million grant from the National Institutes of Health to explore deep brain stimulation in post-stroke motor rehabilitation.

About 3 percent of patients undergoing transcatheter aortic valve replacement (TAVR) also have severe mitral stenosis and are at a greater risk of long-term adverse events, researchers reported in JACC: Cardiovascular Interventions.

The cost of informal caregiving for Americans with heart disease and stroke is projected to more than double over the next two decades, increasing from $61 billion in 2015 to $128 billion by 2035, according to a policy statement published April 9 in Circulation.

Santa Clara, Calif. — April 5, 2018 — Cardiva Medical®, an innovator in the field of vascular closure, today announced the company has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication of the VASCADE® Vascular Closure System. Already approved for use in arterial closure, VASCADE is now FDA approved for use in 5-7F femoral venous closures as well.

A new technique for conducting cardiac MRI can be completed within 90 seconds, allows patients to breathe during testing and could ultimately improve diagnostic accuracy and reliability.

Speedy follow-up with patients after heart failure hospitalizations doesn’t boost medication adherence long-term, researchers reported April 1 in the Journal of the American Heart Association.

DUBLIN — April 9, 2018 — Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension).

People are more likely to prefer a daily cup of tea or a pill over exercise as a treatment options for high blood pressure, according to findings of a survey presented April 7 at the American Heart Association’s Quality of Care and Outcomes Research Scientific Sessions 2018 in Arlington, Virginia.